Breaking News Instant updates and real-time market news.

NVS

Novartis

$78.29

-0.16 (-0.20%)

17:07
10/09/16
10/09
17:07
10/09/16
17:07

Novartis reports data from ASCEND-3, ASCEND-5 trials of Zykadia

Novartis announced updated results from the Phase II ASCEND-3 trial, which demonstrated that anaplastic lymphoma kinase-positive non-small cell lung cancer patients taking Zykadia as their first ALK inhibitor had a median progression-free survival of 18.4 months, with a median follow-up time of 25.9 months. Further, in a sub-analysis of these data, patients who entered the study with brain metastases at baseline experienced an overall response rate of 63.3% and a disease control rate of 83.7%. These results were similar to those in patients without brain metastases, who demonstrated an ORR of 64.0% and DCR of 88.0%. At the time of analysis, the estimated 18-month overall survival rate was 73.4%. This population also demonstrated an ORR of 63.7% and median duration of response of 23.9 months. A decrease in tumor burden from baseline was shown in 94.7% patients. Results from the Phase III ASCEND-5 study were also presented for the first time. The ASCEND-5 study assessed median PFS in patients previously treated with crizotinib and one or two prior regimens of cytotoxic chemotherapy who then received either Zykadia or standard chemotherapy. Results demonstrated a statistically significant and clinically meaningful improvement in median PFS by BIRC for patients taking Zykadia versus chemotherapy. Median PFS by BIRC for Zykadia and chemotherapy were 5.4 months vs. 1.6 months, respectively.

NVS Novartis
$78.29

-0.16 (-0.20%)

08/31/16
LEER
08/31/16
NO CHANGE
Target $61
LEER
Outperform
Teva price target lowered to $61 from $66 at Leerink
Leerink analyst Jason Gerberry lowered his price target for Teva (TEVA) to $61 from $66 on loss of Copaxone patent challenge as an upside catalyst. The analyst believes Teva's share price implies a generic entrant sometime in the second half of 2017 after losing an Inter Partes Review decision on two Copaxone 40mg anchor patents. In order to mitigate EPS downside in 2017-2018 and eliminate business uncertainty, Gerberry thinks the company should settle its Copaxone patent dispute with Novartis (NVS) and Momenta (MNTA), which he sees as "the most credible" generic threat. The analyst reiterates an Outperform rating on Teva's shares.
08/31/16
PIPR
08/31/16
NO CHANGE
PIPR
Piper's Schimmer unsure of impact from Novartis CAR-T shakeup
Piper Jaffray analyst Joshua Schimmer said he's struggling with the implications of the news that Novartis (NVS) is reportedly eliminating its Cell and Gene Therapy unit as a stand-alone entity, which is primarily focused on development of CAR-T and adoptive immunotherapies. On the one hand, removing a leading competitor is a positive for the rest of the field, Schimmer tells investors in a research note. On the other hand, the move by Novartis could signal "significant challenges" in the field, the analyst adds. Schimmer continues to prefer companies "with unique and differentiated approaches," namely Bellicum Pharmaceuticals (BLCM), Cellectis (CLLS), Lion Biotechnologies (LBIO), Amgen (AMGN), Celgene (CELG) and bluebird bio (BLUE). Juno Therapeutics (JUNO) and Kite Pharma (KITE) are down 6% and 5%, respectively, in midday trading.
09/02/16
LEER
09/02/16
NO CHANGE
LEER
Outperform
Teva third Copaxone patent invalidated as expected, says Leerink
Leerink analyst Jason Gerberry says Teva (TEVA) suffered a largely expected loss in its Copaxone 40mg patent battle, with the Patent Trial and Appeal Board, or PTAB, ruling a third patent invalid. The analyst believes the company will likely appeal the loss, along with PTAB rulings rendered last week that other Copaxone patents were invalid. Gerberry sees the bull case scenario of Teva securing patent exclusivity of the Copaxone 40mg as unlikely and says a settlement with Momenta (MNTA) and Novartis (NVS) is the most logical course of action to mitigate 2017-2018E EPS risk. He reiterates an Outperform rating on Teva's shares.
09/20/16
CHDN
09/20/16
INITIATION
Target $95
CHDN
Buy
Novartis initiated with a Buy at Chardan
Chardan initiated Novartis with a Buy and a $95 price target.

TODAY'S FREE FLY STORIES

USO

United States Oil Fund

$12.97

0.19 (1.49%)

06:55
01/24/18
01/24
06:55
01/24/18
06:55
Technical Analysis
United States Oil Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XOP

SPDR Oil Exploration and Production Fund

$39.85

0.16 (0.40%)

06:54
01/24/18
01/24
06:54
01/24/18
06:54
Technical Analysis
SPDR Oil Exploration and Production Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CWST

Casella Waste

$24.26

0.09 (0.37%)

06:54
01/24/18
01/24
06:54
01/24/18
06:54
Upgrade
Casella Waste rating change  »

Casella Waste upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DGAZ

VelocityShares 3x Inv Natural Gas ETN

$20.44

-2.99 (-12.76%)

06:54
01/24/18
01/24
06:54
01/24/18
06:54
Technical Analysis
VelocityShares 3x Inv Natural Gas ETN: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UGAZ

VelocityShares 3x Long Natural Gas ETN

$89.75

10.55 (13.32%)

06:53
01/24/18
01/24
06:53
01/24/18
06:53
Technical Analysis
VelocityShares 3x Long Natural Gas ETN: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EWZ

MSCI Brazil Index

$43.66

-0.97 (-2.17%)

06:52
01/24/18
01/24
06:52
01/24/18
06:52
Technical Analysis
MSCI Brazil Index: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EFA

iShares MSCI EAFE Index Fund

$74.75

0.24 (0.32%)

06:51
01/24/18
01/24
06:51
01/24/18
06:51
Technical Analysis
iShares MSCI EAFE Index Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USAP

Universal Stainless & Alloy

$22.85

0.44 (1.96%)

06:51
01/24/18
01/24
06:51
01/24/18
06:51
Earnings
Universal Stainless & Alloy reports Q4 EPS $1.06 with items vs. (22c) a year ago »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RES

RPC, Inc.

$25.13

-0.28 (-1.10%)

06:50
01/24/18
01/24
06:50
01/24/18
06:50
Hot Stocks
RPC, Inc. raises quarterly dividend by 43% to 10c per share »

The dividend is payable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 15

    May

BHGE

Baker Hughes

$35.82

0.27 (0.76%)

06:49
01/24/18
01/24
06:49
01/24/18
06:49
Hot Stocks
Baker Hughes CEO: Continue to see improvement in activity »

Lorenzo Simonelli, BHGE…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RES

RPC, Inc.

$25.13

-0.28 (-1.10%)

06:49
01/24/18
01/24
06:49
01/24/18
06:49
Earnings
RPC, Inc. reports Q4 adjusted EPS 27c, consensus 34c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 15

    May

PBYI

Puma Biotechnology

$90.90

-3.05 (-3.25%)

06:49
01/24/18
01/24
06:49
01/24/18
06:49
Downgrade
Puma Biotechnology rating change  »

Cowen downgrades Puma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNK

SPDR Barclays High Yield Bond

$36.96

0.11 (0.30%)

06:49
01/24/18
01/24
06:49
01/24/18
06:49
Technical Analysis
SPDR Barclays High Yield Bond: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HZO

MarineMax

06:49
01/24/18
01/24
06:49
01/24/18
06:49
Earnings
Breaking Earnings news story on MarineMax »

MarineMax raises FY18 EPS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

MPX

Marine Products

$13.97

0.17 (1.23%)

06:49
01/24/18
01/24
06:49
01/24/18
06:49
Hot Stocks
Marine Products raises quarterly dividend to 10c per share from 7c per share »

Marine Products announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

SJB

ProShares Short High Yield

$22.99

-0.0507 (-0.22%)

06:48
01/24/18
01/24
06:48
01/24/18
06:48
Technical Analysis
ProShares Short High Yield: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HYG

iShares iBoxx $ High Yield Corporate Bond

$87.88

0.26 (0.30%)

06:48
01/24/18
01/24
06:48
01/24/18
06:48
Technical Analysis
iShares iBoxx $ High Yield Corporate Bond: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$120.18

0.52 (0.43%)

06:48
01/24/18
01/24
06:48
01/24/18
06:48
Technical Analysis
iShares iBoxx $ Investment Grade Corporate Bond: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HZO

MarineMax

06:48
01/24/18
01/24
06:48
01/24/18
06:48
Earnings
MarineMax reports Q1 adjusted EPS 23c, consensus (1c) »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

BHGE

Baker Hughes

$35.82

0.27 (0.76%)

06:47
01/24/18
01/24
06:47
01/24/18
06:47
Hot Stocks
Baker Hughes reports backlog of $21B at Q4-end »

Backlog grew in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLT

iShares 20+ Year Treasury Bond Fund

$123.71

0.53 (0.43%)

06:47
01/24/18
01/24
06:47
01/24/18
06:47
Technical Analysis
iShares 20+ Year Treasury Bond Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MPX

Marine Products

$13.97

0.17 (1.23%)

06:47
01/24/18
01/24
06:47
01/24/18
06:47
Earnings
Marine Products reports Q4 EPS 10c, one estimate 12c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

CS

Credit Suisse

$19.32

-0.02 (-0.10%)

06:47
01/24/18
01/24
06:47
01/24/18
06:47
Periodicals
Credit Suisse CEO says 2018 'started very well', Reuters reports »

Credit Suisse CEO Tidjane…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHGE

Baker Hughes

$35.82

0.27 (0.76%)

06:47
01/24/18
01/24
06:47
01/24/18
06:47
Hot Stocks
Baker Hughes reports Q4 orders of $5.8B »

Up 1% sequentially and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLV

iShares Silver Trust

$16.08

0.04 (0.25%)

06:46
01/24/18
01/24
06:46
01/24/18
06:46
Technical Analysis
iShares Silver Trust: Pivot points, pivot high broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.